BMY Bristol Myers Squibb
Intrinsic value$75.84
Price (at call)$67.66
Margin of safety
+12.1%
vs market (rating basis)
+61.5%
Model unavailable; showing baseline valuation.
⚠ LLM error: empty response; using baseline
The story
Value drivers
| Revenue growth (Y1) | 3.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 27.7% |
| Years to target margin | 5 |
| Sales-to-capital | 0.77 |
| Beta | 0.50 |
| Failure probability | 0.0% |
| Cost of capital (WACC) | 6.8% |
| Terminal WACC | 8.3% |
Valuation bridge
| PV of explicit FCFF | 69.16B |
| PV of terminal value | 120.69B |
| Equity value | 154.91B |
| ÷ shares → per share | $75.84 |
News
neutral +0.15 · 8 articles
- Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services
- What Does Bristol Myers Squibb (BMY) Trial Pause Mean For Its Pipeline?
- Amgen Stock Signals Its Confidence. The Market Agrees.
- Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?
- Can AI Save Pfizer Stock Before Its Patent Cliff Hits?
- How Did Merck Stock Beat The Market With Slowing Sales?
- Bristol Myers Squibb (BMY) Gains On Camzyos Data, Is The Upside Already Priced In?
- Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 50.66B | 3.0% | 27.7% | 10.63B | 1.91B | 8.72B | 8.16B |
| 2 | 52.21B | 3.1% | 27.7% | 10.95B | 2.00B | 8.95B | 7.85B |
| 3 | 53.83B | 3.1% | 27.7% | 11.29B | 2.10B | 9.19B | 7.55B |
| 4 | 55.54B | 3.2% | 27.7% | 11.65B | 2.20B | 9.45B | 7.26B |
| 5 | 57.33B | 3.2% | 27.7% | 12.03B | 2.31B | 9.71B | 6.99B |
| 6 | 59.21B | 3.3% | 27.7% | 12.42B | 2.43B | 9.99B | 6.73B |
| 7 | 61.18B | 3.3% | 27.7% | 12.83B | 2.55B | 10.28B | 6.49B |
| 8 | 63.26B | 3.4% | 27.7% | 13.27B | 2.68B | 10.59B | 6.26B |
| 9 | 65.43B | 3.4% | 27.7% | 13.73B | 2.82B | 10.91B | 6.04B |
| 10 | 67.72B | 3.5% | 27.7% | 14.21B | 2.96B | 11.25B | 5.83B |